Abstract:Background: For patients with psoriatic arthritis (PsA) failing the first TNF-inhibitor, switching to biologic DMARDs [bDMARDs] with different mechanism of actions (swapping strategy) may be superior than switching to another anti-TNF (cycling strategy) [1,2]. Objectives: To evaluate the cost-effectiveness of 1) swapping strategy for established PsA and 2) immediate versus standard swapping strategy for early PsA from the Hong Kong (HK) societal perspective Methods: Based on comparative effectiveness from network meta-analysis of randomized controlled trials and treatment-specific withdrawal and serious adverse event rate, a swapping York model with life time horizon was developed to evaluate swapping strategy relative to best supportive care (BSC) for PsA failing the first anti-TNF. Initial response to bDMARDs was determined using the Psoriatic Arthritis Response Criteria. The impact of biologics on the arthritis component of the disease is modelled via a change in the HAQ and the impact of the skin component measured using the Psoriasis Area and Severity Index. The model was specified for two hypothetical subpopulations including patients with 1) established PsA (age=47, HAQ=1.22, figure 1A) received five swapping strategies and 2) early PsA[3] (age=40, HAQ=0.71, figure 1B) received immediate (start bDMARDs after diagnosis) or standard (initially given BSC and then start bDMARDs when HAQ increase to 1.22) use of the most cost-effective swapping strategy. Both subpopulations were further classified according to the level of concomitant psoriasis [mild to moderate psoriasis (MMP, PASI=0.73) or moderate to severe psoriasis (MSP, PASI=12.5)]. All five swapping strategies started with an anti-TNF (infliximab, adalimumab, etanercept, certolizumab or golimumab), followed by secukinuamb 300 mg and then ustekinumab 45 mg. The cost-effectiveness of each strategy was determined using a willingness-to-pay (WTP) threshold of £32,356/ quality-adjusted life-year (QALY) (HK Gross Domestic Product per capita). Results: For the base-case scenario, all five swapping strategies are cost-effective versus BSC strategy for established PsA, which are associated with greater QALY gain and lower treatment related direct costs, psoriasis cost and productivity loss. In established PsA with MMP and MSP, etanercept swapping strategy is likely to be the most cost-effective strategy with an incremental cost £9,518.93 and £9,084.58 per QALY gained over BSC strategy respectively. For early PsA with MMP and MSP, the base-case results indicated that standard etanercept swapping strategy was cost-saving (£-50,635.74 and £-67,843.32) and more effective (1.20 and 1.32 QALYs); while immediate etanercept swapping strategy was costlier (£13294.95 and £8986.16), more effective (3.82 and 3.27 QALY), and had relative low ICER (£3482.36 and £2745.35 per QALY gained) relative to BSC strategy. Conclusions: Swapping strategy showed favorable cost-effectiveness for established PsA as well as early PsA. The increased costs of biologic agents are offset by the gain in benefits from long-term HAQ reduction. References [1] Merola JF, et al. Semin Arthritis Rheum2017;47:29–37. [2] Cantini F, et al. Semin Arthritis Rheum2017;47:183–192. [3] Kane D, et al. Rheumatology (Oxford)2003;42:1460–8. Disclosure of Interest: None declared

Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK

Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK

Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective

Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany

Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective

Cost-Effectiveness of Biologic Therapies for the Treatment of Moderate to Severe Psoriasis in the United Kingdom

The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland

The Cost-Effectiveness of Anti-IL17 Biologic Therapies for Moderate-to-Severe Plaque Psoriasis Treatment in Italy and Germany: A Sequential Treatment Analysis

Cost per responder of biologic drugs used in the treatment of moderate-to-severe plaque psoriasis in France and Germany

Number Needed to Treat and Costs Per Responder among Biologic Treatments for Moderate-to-severe Psoriasis: a Network Meta-Analysis

Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States

Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis

Sequential interleukin-17 inhibitors for moderate-to-severe plaque psoriasis who have an IL-17 inhibitors failure in a resource limited country: An economic evaluation

Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis

Cost-effectiveness analysis of biologic sequential treatments for moderate-to-severe psoriasis: A Malaysian healthcare system perspective

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study

Cost-Effectiveness Analysis of Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis from a Health Care Provider's Perspective

FRI0616 Cost-effectiveness of swapping strategy for established psoriatic arthritis and immediate versus standard swapping strategy for early psoriatic arthritis

Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison